The antileukemic potential of IHCH9033 was further explored in primary AML cells derived from patients exhibiting variable FLT3-ITD mutant-to-wild allelic ratios (ARs) (Table S1), alongside peripheral blood mononuclear cells (PBMCs) from healthy donors. Here, FLT3 is linked to acute myeloid leukemia.